Efficacy
DISEASE
All 20 patients discontinued the treatments, primarily due to the pathologic progression of the disease defined by RECIST criteria (No patient achieved a CR or PR (ORR = 0%), 25% of patients had stable disease (Efficacy in patients treated with combination DS‐1205c plus gefitinibAbbreviations: BID, twice daily; NR, not reached; PFS, progression‐free survival.